A Smartphone App Reveals Erratic Diurnal Eating Patterns in Humans that Can Be Modulated for Health Benefits.
Shubhroz Gill, Satchidananda Panda
https://pubmed.ncbi.nlm.nih.gov/26411343/Actively Recruiting
Led by National Health Research Institutes, Taiwan · Updated on 2026-04-08
200
Participants Needed
1
Research Sites
11 weeks
Total Duration
This trial investigates the effects of intensive lifestyle interventions on weight loss and cardiometabolic risks in obese adults with metabolic syndrome. It enrolls 200 participants aged 20 to 65 years with metabolic syndrome and a body mass index BMI between 27.0 and 45.0 kgm2. The study aims to compare an intensive lifestyle intervention ILI involving time-restricted eating and increased physical activity with a usual lifestyle intervention ULI over 24 weeks, followed by medication treatment and long-term follow-up to assess sustained weight loss and metabolic improvements. Participants in the ILI group follow a daily 168 fasting pattern eating within 8 hours and fasting for 16 hours, walk more than 10,000 steps daily, and reduce their calorie intake by 500 kcals per day with specific macronutrient distribution. They use a mobile app and a wearable device Fitbit Inspire 2 to track diet and physical activity. The ULI group maintains their usual meal timing and lifestyle. After 24 weeks, both groups are randomly assigned to receive either a GLP-1 receptor agonist Rybelsus or an SGLT-2 inhibitor Forxiga for 26 weeks, with the ILI group continuing their lifestyle regimen. Following medication, all participants are monitored for an additional 52 weeks to evaluate long-term weight maintenance. During the study, researchers collect data on body measurements, biochemical and metabolic variables, and imaging studies including DEXA and abdominal MRI at baseline and follow-ups. Step counts are objectively measured in the ILI group using wearable devices. The primary outcome is the change in metabolic syndrome severity score after achieving more than 5% weight loss at 24 weeks. The study also assesses weight reduction and liver fat content during medication intervention and tracks the sustainability of weight loss over a total of 2.5 years of participation.
CONDITIONS
Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)
V
Vivian Wang, Master
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Health Research Institutes, Taiwan
Lead Sponsor
Tri-Service General Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 24 weeks
Participants either follow an intensive lifestyle program including time-restricted eating and increased physical activity, or maintain their usual lifestyle without intervention.
Regular visits during the 24-week program
Duration - 26 weeks
Participants receive either a GLP-1 receptor agonist (Rybelsus) or an SGLT-2 inhibitor (Forxiga) for 26 weeks, continuing their prior lifestyle regimen.
Regular visits during the 26-week medication phase
Duration - 52 weeks
Participants are followed for an additional period to evaluate long-term weight maintenance.
Periodic visits during the 52-week follow-up
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Shubhroz Gill, Satchidananda Panda
https://pubmed.ncbi.nlm.nih.gov/26411343/Steven B Heymsfield, Joyce B Harp, Marc L Reitman...
https://pubmed.ncbi.nlm.nih.gov/17284728/Salvatore Mottillo, Kristian B Filion, Jacques Genest...
https://pubmed.ncbi.nlm.nih.gov/20863953/David E Laaksonen, Hanna-Maaria Lakka, Jukka T Salonen...
https://pubmed.ncbi.nlm.nih.gov/12196436/Yu-Chung Tsao, Wen-Cheng Li, Wei-Chung Yeh...
https://pubmed.ncbi.nlm.nih.gov/33276457/Jean-Pierre Després, Isabelle Lemieux
https://pubmed.ncbi.nlm.nih.gov/17167477/Leslie O Schulz, Peter H Bennett, Eric Ravussin...
https://pubmed.ncbi.nlm.nih.gov/16873794/Sai Krupa Das, Priya Balasubramanian, Yasoma K Weerasekara
https://pubmed.ncbi.nlm.nih.gov/28412520/Apoor S Gami, Brandi J Witt, Daniel E Howard...
https://pubmed.ncbi.nlm.nih.gov/17258085/Pablo Pérez-Martínez, Dimitri P Mikhailidis, Vasilios G Athyros...
https://pubmed.ncbi.nlm.nih.gov/28521334/National Health Research Institutes, Taiwan
Lead Sponsor
Tri-Service General Hospital
Collaborating Sponsor